Iovance Biotherapeutics Inc. (IOVA)

25.44
0.34 1.30
NASDAQ : Health Technology
Prev Close 25.78
Open 25.80
Day Low/High 25.43 / 26.59
52 Wk Low/High 7.26 / 26.07
Volume 971.92K
Avg Volume 1.91M
Exchange NASDAQ
Shares Outstanding 123.51M
Market Cap 3.02B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Looks Good and I'm Buying

Biotech Looks Good and I'm Buying

The sector has been a great trading group lately and I bought these 2 names this morning.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

The Stock Market Is Facing One Big Obstacle Right Now

The Stock Market Is Facing One Big Obstacle Right Now

You have to wonder how much longer we can run without a pullback of at least 2%.

Short Interest In Iovance Biotherapeutics Expands By 16.3%

Short Interest In Iovance Biotherapeutics Expands By 16.3%

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 515,385 share increase in total short interest for Iovance Biotherapeutics Inc , to 3,671,492, an increase of 16.33% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of IOVA February 2018 Options Trading

First Week of IOVA February 2018 Options Trading

Investors in Iovance Biotherapeutics Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Short Interest In Iovance Biotherapeutics Expands By 31.3%

Short Interest In Iovance Biotherapeutics Expands By 31.3%

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 741,148 share increase in total short interest for Iovance Biotherapeutics Inc , to 3,107,847, an increase of 31.32% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data From Metastatic Melanoma Trial To Be Presented At SITC Meeting

Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data From Metastatic Melanoma Trial To Be Presented At SITC Meeting

Late-Breaking Poster Shows Early Efficacy Data in Nine Patients Treated with Cryopreserved TIL Product LN-144; Comparable Safety to Non-Cryopreserved LN-144

Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

- Company to Host Conference Call at 4:30pm ET Today -

First Week of IOVA November 17th Options Trading

First Week of IOVA November 17th Options Trading

Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new November 17th contracts and identified the following put contract of particular interest.

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

The Seattle firm is selling it three marketed hyperimmune products to Saol Therapeutics. Separately, Aptivo announced the end of its partnership with MorphoSys regarding a potential treatment for prostate cancer.